Eltoprazine

Eltoprazine (developmental code name DU-28,853) is a serotonergic drug of the phenylpiperazine class which is described as a serenic, or anti-aggressive agent.

It acts as an agonist of the serotonin 5-HT_1A and 5-HT_1B receptors and as an antagonist of the serotonin 5-HT_2C receptor. The drug is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan.

Eltoprazine was first described in the scientific literature by 1987. It is or was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognitive disorders, and drug-induced dyskinesia, but no recent development has been reported for these indications as of February 2022. It was also under development for the treatment of psychotic disorders, but development for this indication was discontinued. Eltoprazine is said to have shown signs of effectiveness for treatment of aggression, but was rejected for marketing authorization on the basis of the fact that aggression is a symptom rather than a disorder. The drug was originated by Solvay and was developed by Elto Pharma, PsychoGenics, and Solvay.